Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola
Rossella R
RR
Section of Hematology, Department of Biomedical Science, University of Catania, Catania, Italy. rcacciol@unict.it
Di Francesco
Ernesto
E
Pezzella
Francesca
F
Tibullo
Daniele
D
Giustolisi
Rosario
R
Cacciola
Emma
E
D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy*; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology
D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C045879:prothrombin fragment 1.2; D010978:Platelet Factor 4; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases; C021139:anagrelide; D001241:Aspirin; D006918:Hydroxyurea